TOP STORIES
respiratory
Podcast

Prof Bruce Thompson: what to expect in respiratory medicine in 2021

A year into the coronavirus pandemic and with a vaccine finally approved by the TGA for use in Australia we speak with TSANZ president Professor Bruce Thompson about vaccine rollout and how COVID-19 will continue to affect the field of...

A year into the coronavirus pandemic and with a vaccine finally approved by the TGA for use in Australia we...

Read more
Cystic Fibrosis

Benefits of cystic fibrosis combination therapies maintained in the long-term: trials

Treatment with lumacaftor-ivacaftor (Orkambi) was tolerated well and maintained its efficacy in children aged 6-11 years out to 120 weeks, according to long-term trial data. Previous trials have demonstrated success with the combination therapy in children homozygous for the F508del-CFTR mutation...

Treatment with lumacaftor-ivacaftor (Orkambi) was tolerated well and maintained its efficacy in children aged 6-11 years out to 120 weeks,...
Medicines

People with asthma are at less risk of COVID-19, but why?; Trial sheds light on how azithromycin reduces asthma exacerbations; Huge spike in RSV in kids sends a public health message 

People with asthma are at less risk of COVID-19, but why? People with asthma are not at increased risk for acquiring COVID-19 compared to those without asthma and have similar clinical outcomes, a review concludes. The systematic review of 57 studies by...

People with asthma are at less risk of COVID-19, but why? People with asthma are not at increased risk for acquiring...
End-of-life care

End-of-life patient experience shows unmet need in non-cancer respiratory disease

The trajectories of functional decline and overall symptom burden are surprisingly similar in patients with end-stage lung cancer and those with non-malignant end-stage respiratory diseases. The evidence supports the ongoing call for improved access to palliative care in non-cancer patients. According to...

The trajectories of functional decline and overall symptom burden are surprisingly similar in patients with end-stage lung cancer and those...